BioCryst Pharmaceuticals Inc. (BCRX)

2.24
0.13 6.16
NASDAQ : Health Technology
Prev Close 2.11
Open 2.10
Day Low/High 2.05 / 2.26
52 Wk Low/High 1.38 / 9.95
Volume 3.57M
Avg Volume 1.96M
Exchange NASDAQ
Shares Outstanding 148.37M
Market Cap 300.45M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Caution, not aggression, will be the rule next week, Cramer says.

Interesting BCRX Put And Call Options For May 17th

Interesting BCRX Put And Call Options For May 17th

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the May 17th expiration.

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

BioCryst Announces Nature Publication Demonstrating Efficacy Of BCX4430 In A Non-Human Primate Model Of Filovirus Infection

BioCryst Announces Nature Publication Demonstrating Efficacy Of BCX4430 In A Non-Human Primate Model Of Filovirus Infection

Broad Spectrum Activity Shown Against Multiple RNA Virus Biothreats

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Interesting BCRX Put And Call Options For April 19th

Interesting BCRX Put And Call Options For April 19th

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the April 19th expiration.

First Week Of BCRX September 20th Options Trading

First Week Of BCRX September 20th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the September 20th expiration.

Biocryst Pharmaceuticals (BCRX) Is Today's Perilous Reversal Stock

Biocryst Pharmaceuticals (BCRX) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

BioCryst Receives Additional NIAID Funding To Advance Development Of BCX4430 To Treat Marburg Virus Disease

BioCryst Receives Additional NIAID Funding To Advance Development Of BCX4430 To Treat Marburg Virus Disease

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling...

BioCryst Files Peramivir NDA For The Treatment Of Influenza

BioCryst Files Peramivir NDA For The Treatment Of Influenza

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New ...

BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors For Hereditary Angioedema Into Preclinical Development

BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors For Hereditary Angioedema Into Preclinical Development

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the ...

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the following investor...

BCRX January 2016 Options Begin Trading

BCRX January 2016 Options Begin Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading today, for the January 2016 expiration.

January 2015 Options Now Available For BioCryst Pharmaceuticals (BCRX)

January 2015 Options Now Available For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading today, for the January 2015 expiration.

BioCryst Initiates OPuS-1: A Phase 2a Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema

BioCryst Initiates OPuS-1: A Phase 2a Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in OPuS-1 ( Oral Prophylaxi S-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in...

BioCryst Provides Corporate Update And Reports Third Quarter 2013 Financial Results

BioCryst Provides Corporate Update And Reports Third Quarter 2013 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2013.

6 Charts Explain An Ugly October for Biotech Stocks

6 Charts Explain An Ugly October for Biotech Stocks

For only the second time in 2013, the S&P 500 beat biotech stocks in October.

BioCryst To Announce Third Quarter 2013 Financial Results November 5

BioCryst To Announce Third Quarter 2013 Financial Results November 5

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2013 financial results will be released on Tuesday, November 5, 2013.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

3 Biotech Stocks Under $10 Making Big Moves

3 Biotech Stocks Under $10 Making Big Moves

Keep these under-$10 biotech stocks on your radar.

BioCryst Awarded Contract By The National Institute Of Allergy And Infectious Diseases (NIAID) To Develop BCX4430 For The Treatment Of Marburg Virus Disease

BioCryst Awarded Contract By The National Institute Of Allergy And Infectious Diseases (NIAID) To Develop BCX4430 For The Treatment Of Marburg Virus Disease

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has contracted with BioCryst for the development of BCX4430 as a treatment...

BioCryst To Present At Morgan Stanley Global Healthcare Conference

BioCryst To Present At Morgan Stanley Global Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the ...

Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin

Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

TheStreet Quant Rating: D- (Sell)